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esponsibility of Xi’Abstract Risk assessment and uncertainty approximation are two major and important parameters that
need to be adopted for the development of pharmaceutical process to ensure reliable results. Additionally,
there is a need to switch from the traditional method validation checklist to provide a high level of assurance
of method reliability to measure quality attribute of a drug product. In the present work, evaluation of risk
proﬁle, combined standard uncertainty and expanded uncertainty in the analysis of acyclovir were studied.
Uncertainty was calculated using cause-effect approach, and to make it more accurately applicable a method
was validated in our laboratory as per the ICH guidelines. While assessing the results of validation, the
calibration model was justiﬁed by the lack of ﬁt and Levene’s test. Risk proﬁle represents the future
applications of this method. In uncertainty the major contribution is due to sample concentration and mass.
This work demonstrates the application of theoretical concepts of calibration model tests, relative bias, risk
proﬁle and uncertainty in routine methods used for analysis in pharmaceutical ﬁeld.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Measurements are made and used to make decisions. Whenever
we use numbers to make decisions, we run the risk of making a
mistake because all numbers are more or less unreliable. If we
measure something, we can be certain of only one thing: thesity. Production and hosting by Else
5
o.com (R.C. Mashru).
an Jiaotong University.measurement is dicey. Since every measurement is doubted, we
should know how and why it is so. With the contemporary
development of analysis ﬁeld errors, doubted results are also
increasing. Therefore, to avoid these doubts recently a newer
approach has been introduced known as measurement of uncer-
tainties in analysis of a sample. As the result of measurement is
only an estimation of the measurand value (m), it is accepted only
when accompanied by a quantitative statement of its uncertainty
(U) and is expressed as (mþU). Managing uncertainty is a basic
effort in analytical method development and validation. Thevier B.V. All rights reserved.
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uncertainty nowadays has become an important parameter for a
validated method to get accreditation [1,2].
In 2012, Eurachem introduced the third edition of guidelines for
quantifying uncertainty in analytical measurement based upon
developments in uncertainty estimations [3]. The most important
characteristic of a properly calculated uncertainty budget, com-
pared to other measures of method performance, is that it
encompasses on both random and systematic effects to give a
single value. For the uncertainty estimation, the steps involved
start with measurand speciﬁcation and end with expanded uncer-
tainty (EU) calculation.
Nowadays, heaps of analytical methods have been introduced
and published worldwide for the estimation of drug contents in
pharmaceutical formulations. But as literature suggests and to our
best knowledge, validation by total error approach and quantiﬁca-
tion of sources of uncertainties in these methods have been
missing. However, a few methods are there, but they are lacking
in explanation of simple ways for quantifying uncertainty compo-
nents, combined standard uncertainty (CSU) and EU. Thus to
enlighten the total error approach in pharmaceutical ﬁeld, in the
current study a simple methodology for quantiﬁcation of uncer-
tainty components and CSU is presented by assessing these
computations for spectrophotometric measurement of acyclovir
in its different formulations. To have a detailed and accurate study
of uncertainty components, a new UV method for acyclovir and its
different dosage forms has been developed and validated as per the
ICH guidelines [4,5]. β-expectation tolerance interval, relative
bias, accuracy proﬁles, risk proﬁle and calibration model were
studied. This approach also includes detailed analysis of the
factors inﬂuencing analytical results using cause-effect diagram,
and risk proﬁle of future assessment.
Acyclovir (9-[(2-hydroxyethoxy)-methyl]-guanine) is the most
widely used antiviral agent in our community. It is an acyclic
guanosine derivative with clinical activity against HSV-1, HSV-2
and against varicella-zoster virus. It has also been used in the
treatment of primary and recurrent genital herpes, herpes simplex
encephalitis and neonatal HSV infection [6–8]. It has been shown
that acyclovir has high solubility and low intestinal permeability
and considered as a typical class III drug according to The
Biopharmaceutics Classiﬁcation System (BCS) from the Food
and Drug Administration (FDA) of the United States [9,10]. The
therapeutic importance of acyclovir has promoted the development
of many analytical methods for its quantitative determination.
These methods include high-performance liquid chromatography
(HPLC) [11–21], micellar liquid chromatography [22], gas chro-
matography [23], capillary electrophoresis [24], and radioimmu-
noassay [25]. Spectrophotometric analyses are considered as more
convenient alternative techniques because of their inherent sim-
plicity and high sensitivity. Since, acyclovir contains a weakly
absorbing chromophore, few spectrophotometric methods [26–29]
have been reported for their determination, but all these methods
are laborious, time consuming or/and require derivatization of
the drug.
Uncertainty estimation and β-expectation tolerance interval,
relative bias, accuracy proﬁles, risk proﬁle and calibration model,
which were not studied either, are critical parameters in today’s
method validation procedures. Some articles propose the conven-
tional estimation of analytical measurements and uncertainty as
well [30–33]. However, most of these methods are applied to food
samples and a very few methods have been found for pharma-
ceutical formulations [34]. Therefore, we developed a new simplespectrophotometric method that overcomes these drawbacks by
applying a wide uncertainty estimation and total error estimation
approach.2. Experimental
2.1. Instrumentation
Spectrophotometric measurements were made on a Shimadzu
1700 double beam UV–vis spectrophotometer with a ﬁx slit width
of 1 nm coupled with Shimadzu UV PC software (UV probe)
version 2.31. Weighing balance of Shimadzu AX120, bath
sonicator (Electroquip) and borosil glass apparatus were used for
experimental purpose.
2.2. Materials and reagents
Pure acyclovir was procured as gift sample from Nestor Pharma-
ceutical Pvt. Ltd., India. Various commercial formulations of
acyclovir were purchased from local drug store. All the reagents
used in this study were of analytical grade. Double distilled water
was used for the preparation of the solutions, and for robustness
studies HPLC grade and single distilled water were used.
2.3. Preparation of standard solutions
An accurately weighed amount of acyclovir was transferred into a
10 mL calibrated ﬂask and dissolved in approximately 4 mL of
0.1 M HCl. The resulting solutions were completed to the mark
with 0.1 M HCl obtaining stock standard solution containing
1000 mg/mL. Different volumes of this stock solution were then
further diluted with 0.1 M HCl to obtain the working standard
solutions.
2.4. Sample preparation for different formulations
2.4.1. Optimization of sonication time
Sonication time used in the preparation of samples of different
formulations was optimized for all the different matrices by trial
methods.
2.4.2. Tablets
Twenty tablets were ﬁnely powdered and an accurately weighed
quantity of the powdered tablets content equivalent to 10 mg of the
active ingredient was transferred into a 10 mL calibrated ﬂask and
dissolved in about 6 mL of 0.1 M HCl. The contents of the ﬂask
were swirled, sonicated up to 9 min and then volume of the ﬂask
was made up with 0.1 M HCl. The contents were mixed well,
ﬁltered and the ﬁrst portion of the ﬁltrate was rejected. The
prepared solution was diluted quantitatively with the 0.1 M HCl to
obtain a suitable concentration for analysis.
2.4.3. Cream samples
An accurately weighed amount of the cream equivalent to 10 mg
of acyclovir was shaken with 5 mL of 0.1 M HCl and sonicated for
15 min and then the volume was made up to the mark with 0.1 M
HCl. The resulting solution was ﬁltered and the ﬁrst portion of the
ﬁltrate was discarded. The working solutions were prepared by
further diluting with 0.1 M HCl for analysis.
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Eye ointment equivalent to 10 mg of acyclovir was dispersed in
few mL of 0.1 M HCl, sonicated for 18 min and the volume was
made up with 0.1 M HCl. The resulting solution was ﬁltered, and
the ﬁrst portion of the ﬁltrate was rejected. The working solution
was prepared by further diluting with 0.1 M HCl for analysis.
2.4.5. Injection
To determine the drug in injectable dosage form, the contents per
injection were diluted with 0.1 M HCl and then sonicated for
9 min and the volume was made up with 0.1 M HCl. The resulting
solution was ﬁltered, and the ﬁrst portion of the ﬁltrate was
rejected. The working solution was prepared by further diluting
with 0.1 M HCl for analysis.
2.5. Procedure for spectrophotometric determination
All reagents were tested for stability in solution and during the
actual analysis. The behavior of analyte remained unchanged for
about 24 h from their preparation at room temperature. The drug
was found to be stable during each kind of experimental
measurements. Each measurement was done at room temperature.
The absorption spectra of the standard solutions were recorded
between 200-400 nm against a reagent blank (the same for samples
without the analyte to be determined) using a 1.0 cm quartz cell.
The zero-order spectrum of pure drug was obtained and absorption
maxima was found to be at 257 nm.
2.6. Validation parameters studied using total error approach
The present method was validated according to the ICH [4,5] and
the ISO-17025 applying accuracy proﬁles, which are based upon
the “total error” approach [1]. This approach estimates the “total
error” by combining the systemic error (trueness) and the random
error (intermediate precision) to know the difference between the
observed result and the true value. In other words, the highest error
of an analytical method can be estimated. In the proposed method
different parameters such as sensitivity, robustness and assay
determination were also studied.
2.7. Response function (calibration curve)
In the proposed method four sets of calibration curve were plotted
between absorbance and different concentrations of acyclovir
which follows Lambert–Beer’s law and on these four different
series regression analysis was performed and the series with best
coefﬁcient of determination was selected and the selected linearity
has been diagnosed by the Lack of Fit, Levene’s test and standard
residual plot.
2.8. Trueness
According to the ISO, trueness of an analytical procedure
expresses the closeness of agreement between the average value
obtained from repeated measurements and a conventional true
value [35]. In this method trueness of calibration curve is
calculated to justify the calibration line by back calculating
concentrations and results are expressed in terms of absolute and
relative bias, and also a linear relationship between introduced and
back calculated concentrations has been plotted to demonstrate
method linearity.2.9. Precision
The precision of an analytical method expresses the closeness of
agreement between the values obtained from repeated measure-
ments. In this method precision at two levels was studied: the ﬁrst
one was repeatability under the same operating conditions over a
short time interval and the second was the intermediate precision
assessed on different days. The precision results are expressed
using relative standard deviations (RSD). Relative precision and
absolute precision at these two levels were calculated and also
95% upper conﬁdence limit for both levels was calculated.
2.10. Accuracy
Accuracy is the most critical parameter in method validation, so it
requires an extra care during the study. Therefore, the results of
accuracy studies were represented in the β-expectation tolerance
limits. In addition to this, risk proﬁle was also studied to know the
future application of the method in different matrices. Accuracy
proﬁles for the four different matrices were plotted with β-
expectation tolerance limits. Linearity proﬁle was also studied to
demonstrate the relationship between nominal and observed
concentrations in different matrices and furthermore, residual
plot was generated to know the outliers in the determination of
acyclovir in sample matrix.
2.11. Limit of detection and quantiﬁcation
Limit of detection (LOD) and limit of quantiﬁcation (LOQ) are
two important parameters which show the application of methods
in quantiﬁcation and detection of different samples. These were
calculated according to the procedure mentioned in the ICH
guidelines [4,5].
2.12. Robustness
In daily routine analysis some human or system errors are always
there in sample preparation and system measurement properties. A
method should be steady to avoid these errors or small variations
and should not deviate from its capability of producing reliable
results. So, to conﬁrm this robustness studies were performed.
Robustness was examined by evaluating the inﬂuence of small
variation of method variables including solvent grades and
detection wavelengths. In these experiments, one parameter was
changed whereas the others were kept unchanged and recovery
percentage was calculated each time and for all the formulations,
recovery experiments for robustness studies were also planned and
studied. The robustness studies were conducted with three
different wavelengths and three different grades of solvent (HPLC,
SD, DD). The study was conducted by keeping one standard
parameter constant and varying the second factor respectively.
2.13. Application of proposed method to analysis of dosage
forms
After the conﬁrmation of method capacity to analyze acyclovir, it
was subjected to the analysis of different formulations for their
contents of acyclovir. The results for different matrices were
calculated in terms of percentage purity. These results conﬁrmed
the capacity and reliability of the developed method.
Risk silhouette and uncertainty approximation 612.14. Identiﬁcation and quantiﬁcation of different uncertainty
parameters
Although the method was validated, still there were some doubts
in the results, as few factors were not included in the validation
such as errors during mass of sample taken. So uncertainty
estimation was carried out starting with the identiﬁcation of
sources of uncertainty and compiled up with the CSU and EU
results.
2.14.1. Construction of the cause-effect diagram
In order to list uncertainty sources, it is very convenient to use the
cause-effect diagram because it shows how the sources link to
each other and indicate their inﬂuence on the result. So a cause-
effect diagram was constructed as shown in Fig. 1, which points
out the different sources which may affect the sample analysis
measurement. These parameters are volume of volumetric ﬂask
V10, concentration of analyte C10, mass of sample, recovery of
method Rm and precision of method. All these parameters
contribute to the overall uncertainty in ﬁnal analytical results in
marketed formulations. This diagram will also help in resolving
any repeatability of components in uncertainty. These parameters
are shown in Eq. (1).
Acyclovirsample ¼ C10V10103=msampleRm ð1Þ
where, Acyclovirsample, acyclovir quantity (mol/kg); C10, acyclovir
concentration in 10 mL volumetric ﬂask (M); V10, volume of
10 mL volumetric ﬂask (mL); msample, acyclovir sample mass
taken (kg); Rm, Recovery of method.
Now after identiﬁcation, these sources were quantiﬁed and their
individual effect on overall uncertainty was studied and compiled
up in the form of CSU and EU by carefully choosing coverage
factor.2.15. Individual parameters effecting overall uncertainty
2.15.1. Discharge of volumetric ﬂask
The uncertainty due to discharge of volumetric ﬂask was evaluated
by performing experiment consisting of ﬁlling up and weighing
10 mL volumetric ﬂask with standard solution repeatedly for
10 times.Fig. 1 Cause-effect diagram constructed to identify the sources of uncer
precision of method, recovery of method, volume of volumetric ﬂask V102.15.2. Recovery of method
Uncertainty associated with the recovery of method depends upon
the concentration spiked and recovery of sample observed, so for
all the formulations recovery was simply calculated by Eq. (2) and
uncertainty associated with recovery of method was evaluated
using Eq. (3) [36].
Rm ¼
Cobs
Cspike
ð2Þ
where Cobs, replicate analysis of spiked sample; Cspike, nominal
concentration of acyclovir in spiked sample.
UðRmÞ ¼ Rm 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S2obs
n  C2obs
 
þ UðCspikeÞ
Cspike
 2s
ð3Þ
where Sobs, standard deviation of results from the replicate
analyses of spiked sample; n, number of replicates; U(Cspike),
standard uncertainty in concentration of spiked sample.
2.15.3. Concentration (C10)
The acyclovir sample concentration uncertainty is expressed as
concentration uncertainty from calibration curve and is given by
Eq. (4).
UðcÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
þ 1
p
þ ðc cÞ
2
Sxx
s
ð4Þ
where
Sr ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑nj ¼ 1½ Yjðbxiþ aÞ
q
n2
Sxx ¼∑ðCicÞ2
Sr, residual standard deviation; n, number of measurements
used for calibration curve; p, number of measurements used to
obtain concentration of the sample; C, acyclovir concentration in
sample (M); c, average of standard solution (M); Yj, analytical
signal of the measurement; j, index for number of measurements
made in order to obtain the calibration curve; i, index for number
of solution for calibration; b, slope of calibration curve (L/mol); a,
calibration curve intercept.
The sample solution was measured 10 times (p¼10) and
concentration was obtained from the calibration curve regressiontainty. The major identiﬁed sources are concentration of sample C10,
and sample mass.
Table 1 Results of LOF and Levene’s test for linear regression model.
Test Error SS df MS Fcalc Fcrit, 95% p-Value
Lack of Fit LOF error 0.0001047 16 0.00000873 1.775 1.918 0.1046
Pure error 0.0001475 38 0.00000492
Levene’s Model 0.0000142 5 0.00000285 1.886 2.380 0.1173
Error 0.0000634 56 0.00000151
K. Mittal et al.62equation Eq. (5).
Y ¼mxþ c ð5Þ
where Y, absorbance of sample; c, calibration curve intercept; m,
calibration curve slope; x, concentration of acyclovir.
2.15.4. Sample mass (msample)
The sample mass was obtained by calculating difference between
weighing glass with and without the acyclovir sample.
2.15.5. Precision of method (P)
The precision branch collects terms which contribute to random
variability of the entire method. Estimate of precision is available
from replicate analysis of samples. When the precision studies
were carried out and data were obtained, the repeatability and
variability associated with that measurement were included in the
overall precision uncertainty estimation.Fig. 2 Standard residual plot of four different series representing
absence of outliers in all different concentration levels.
Table 2 Results of trueness in terms of relative bias (%).
Nominal
concentration
(mg/mL)
Back calculated
concentration
(mg/mL)
Absolute
bias
(mg/mL)
Relative
bias (%)
2.000 2.038 0.03754 1.877
4.000 3.952 0.04821 1.205
6.000 5.974 0.02588 0.4313
8.000 7.949 0.05130 0.6413
10.00 10.04 0.03764 0.3764
12.00 12.00 0.000905 0.007543. Results and discussion
The absorption spectrum of acyclovir was recorded and it shows
the maximum absorption intensity at 257 nm. Thus all the studies
were carried out at the same wavelength (nm).
3.1. Validation parameters
3.1.1. Response function (calibration curve)
In the proposed method calibration curves were prepared using linear
regression model. Four different sets were prepared for response
function studies within the range of acyclovir from 2 to 12 mg/mL. As
four sets were prepared, all of them were found to follow the linear
regression model and their regression analysis parameters results were
studied. As from regression analysis studies, series 4 shows the best
coefﬁcient of determination r2 as 0.9999 with regression
equation (Y¼0.08083X–0.001444), which was selected for further
studies and computation. Furthermore, the linear regression model was
also conﬁrmed for its suitability for method by diagnosis using Lack of
Fit (LOF) test and Levene’s test. As p-values were found to be higher
than 0.05, represented in Table 1 to demonstrate that no outliers were
found in calibration curve, standard residual plot was also plotted as
shown in Fig. 2. Now to conﬁrm the chosen regression equation, back
calculation was done and linear plot based upon absolute β-expectation
limit was generated between nominal and back calculated concentration
which shows r2 value is 0.9998 and it becomes clear that the
calibration lines adequately describe the observed relationship.
3.1.2. Trueness
To justify the trueness of the method percentage relative bias was
calculated and is illustrated in Table 2 from where it can be
concluded that the trueness for all different concentrations isacceptable, since the percentage relative bias is limited between
0.641% and 1.87%.
3.1.3. Precision
The results of precision were found to be o2% in terms of RSD
for both repeatability and intermediate levels. These results of
intermediate and repeatability precision suggest that the developed
analytical method was precise and reproducible. The results of
relative and absolute intermediate precision and repeatability are
shown in Table 3 which justiﬁes the reproducibility of method and
further 95% conﬁdence upper limit has been demonstrated in
Table 3 for both intermediate precision and repeatability.
3.1.4. Accuracy
The accuracy of the method was carried out by standard addition
method. Accuracy takes into account the total error of the test
results and is represented by the β-expectation tolerance limits.
The method accuracy was performed using different matrices
Table 3 Results of relative and absolute intermediate precision and repeatability in terms of %RSD.
Nominal concentration
(μg/mL)
Relative intermediate precision and repeatability Absolute intermediate precision and repeatability
Repa
(%RSD)
IPb
(%RSD)
95% Upper
conﬁdence limit
Repa (SD)
(μg/mL)
Between-series
(SD) (μg/mL)
Ration of variance
components
(between/within)
IPb (SD)
(μg/mL)
Repa (SD)
(μg/mL)
IPb (SD)
(μg/mL)
2.000 0.4252 0.5263 0.0161 0.0663 0.1183 0.0677 0.0136 0.0405
4.000 0.4857 0.5657 0.0353 0.0353 0.0473 0.0184 0.1521 0.0507
6.000 0.4184 0.5586 0.0937 0.0513 0.0395 0.0226 0.3277 0.0455
8.000 0.2134 0.2877 0.0662 0.0770 0.0227 0.0039 0.0304 0.0230
10.00 0.2544 0.3493 0.0822 0.0566 0.0514 0.0193 0.1402 0.0549
12.00 0.2152 0.3619 0.0750 0.0697 0.0630 0.0239 0.1441 0.0674
aRep – Repeatability.
bIP – Intermediate precision.
Table 4 Result of method accuracy in terms of relative beta-expectation tolerance limit and risk assessment obtained by selected
regression model in different matrices.
Matrix Concentration
level (%)
Concentration
(mg/mL)
Beta-
expectation
tolerance limits
(mg/mL)
Relative beta-
expectation
tolerance limits (%)
Riska (%)
Tablet 80.0 8.000 [7.91, 8.10] [1.17, 1.30] 0.000339
100.0 10.00 [9.89, 10.09] [1.10, 0.90] 0.000048
120.0 12.00 [11.95, 12.06] [0.44, 0.52] 0.00000003
Cream 80.0 8.000 [7.92, 8.13] [1.02, 1.65] 0.000832
100.0 10.00 [9.79, 10.10] [2.06, 1.05] 0.003895
120.0 12.00 [11.85, 12.20] [1.24, 1.66] 0.001583
Ointment 80.0 8.000 [7.86, 8.09] [1.78, 1.08] 0.001602
100.0 10.00 [9.97, 10.15] [0.34, 1.45] 0.000029
120.0 12.00 [11.75, 12.19] [2.05, 1.59] 0.01124
Injection 80.0 8.000 [7.92, 8.13] [0.9815, 1.623] 0.000667
100.0 10.00 [9.80, 10.09] [1.970, 0.9440] 0.002294
120.0 12.00 [11.85, 12.21] [1.281, 1.708] 0.002071
aRisk of having measurements falling outside of the acceptance limits (75%).
Risk silhouette and uncertainty approximation 63and thus accuracy obtained by considering linear regression
model has been summarized in Table 4. It was also found that
the β-expectation tolerance limits do not exceed the acceptance
limits which means that β-percent (95%) of the future measure-
ment of unknown samples will be included within the tolerance
limits as shown by accuracy proﬁle illustrated in Fig. 3.
Accuracy proﬁle of the method was also justiﬁed by risk proﬁle
by choosing maximum risk level at 5.0% and it was concluded
that the risk of outliers are within limits and future analysis of
unknown sample will fall within the range. To evaluate the
errors in intra accuracy studies a linear plot was also generated
which shows the linearity between nominal and observed
concentrations with r2 as 0.9989 and also conﬁrms the outliers
in different spiking concentrations. A standard residual plot was
plotted, which shows that there are no outliers falling in the intra
accuracy studies as shown in Fig. 4.3.1.5. Limit of detection and quantiﬁcation
Results of LOD and LOQ show that this method is sensitive
enough to analyze the marketed formulations. Values of LOD
and LOQ were found to be 0.255 and 0.772 mg/mL,
respectively.3.1.6. Robustness studies
Robustness of the developed method was determined in the
form of percentage RSD by small but deliberate changes in the
solvent grade and detection wavelength in all the sample
matrices. The results of robustness studies are represented in
Table 5 showing the effect of variation on amount found in
sample matrix and from these results it is concluded that the
method has enough capacity to bear up to some extent human
or system errors.
Fig. 3 Accuracy proﬁle of acyclovir determination in (A) tablets, (B) skin cream, (C) eye ointment, (D) injection obtained after application of
linear regression using calibration standards prepared with the matrix. The plain line is the relative bias, the dashed lines are the 95% β-expectation
tolerance limits and the dotted curves represent the acceptance limits (7 5%). The dots represent the relative back calculated concentrations of the
validation standards.
K. Mittal et al.643.2. Application of the proposed method to analysis
of dosage forms
3.2.1. Sonication time optimization
As the matrices are different, the extraction time of acyclovir from
them will be different. To achieve the maximum extraction of
acyclovir, optimization of sonication time was carried out by
analyzing samples after different sonication times. The most
suitable sonication time for tablet, skin cream, eye ointment and
injection was found to be 9, 15, 20, and 9 min, respectively. After
sonication for these particular time period, percentage purity for all
formulations was found to be in the range of 99–101%.3.2.2. Analysis of dosage form
It is evident from the aforementioned results that the proposed
method gave satisfactory results with the drug. Thus dosage
forms were subjected to analysis for their contents of active
drug material by the proposed method. The percentage purityfor skin cream, eye ointment, tablet and injection was found to
be 99.75, 101.36, 100.9 and 99.21, respectively. It is evident
from the above mentioned values that the proposed method is
applicable to the analysis of drug in its bulk and dosage forms
with comparable analytical performance. The critical recom-
mendations of this method might be based on their relative
sensitivities (that determines the amount of specimen available
for analysis) and experimental conditions (sonication time,
diluting solvent, etc.).3.3. Measurement of uncertainty
After the uncertainty sources were identiﬁed according to the
cause–effect diagram, they were evaluated, their magnitude was
determined, and in order to assure the traceability for uncertainty
results all the calculations were done in the International System of
Units as concentration in M and weight in kg.
Fig. 4 Standard residual plot conﬁrming absence of outliers in determination of accuracy of (A) tablets, (B) skin cream, (C) eye ointment and
(D) injection.
Risk silhouette and uncertainty approximation 653.3.1. Uncertainty due to concentration (C10)
After the scanning of standard solution, values in terms of
absorbance were obtained and calibration curve was plotted as
described by Eq. (5). Regression equation of calibration curve was
identiﬁed as slope 10,746 and intercept 0.079. For the determina-
tion of calibration curve, six solutions were measured three times
(total number of measurements, n¼18). The sample solution was
measured 10 times, thus obtaining analyte concentration in tablet,
cream, ointment and injection. Results are represented in Table 6.
Thus:
Sxx ¼ 1:142 109 ð6Þ
Sr ¼ 3:037 102 ð7Þ
Then using Sr and Sxx, standard relative uncertainty due to
concentration was calculated and results are expressed in Table 7.
A very small difference was observed in the standard relative
uncertainty of different formulations.3.3.2. Uncertainty of the liberation of 10 mL volume of 10 mL
volumetric ﬂask
The effect on volume of 10 mL volumetric ﬂask is mainly
inﬂuenced by the three parameters, i.e. calibration of the volu-
metric ﬂask (at the time of manufacturing), repeatability and
temperature.
3.3.2.1. Calibration of volumetric ﬂask. Deviation of value from
nominal volume for 10 mL volumetric ﬂask was70.007 mL (at
27 1C) as given by the manufacturer and by assuming that standard
deviation is not claimed by the manufacturer with conﬁdence
interval limit, standard value of uncertainty can be calculated with
triangular distribution. Thus, uncertainty associated with liberation
of 10 mL volume of 10 mL volumetric ﬂask due to calibration u
(V10cal) is shown in Eq. (8).
uðV10 calÞ ¼
0:007ﬃﬃﬃ
6
p ¼ 2:86 103 mL ð8Þ
3.3.2.2. Repeatability u(V10rep). After ﬁlling and weighing
10 mL volumetric ﬂask, standard uncertainty of volumetric ﬂask
was established at 0.0014 mL.
Table 5 Result of robustness studies in different variations in terms of mean concentration found and %RSD (n¼6).
Parameters studied Nominal concentration (mg/mL) Mean concentration found (mg/mL) 7%RSD
Tab. Crm. Ont. Inj.
Solvent grade HPLC 10 9.9870.79 10.0170.32 9.9970.35 9.9870.35
SDa 10 9.9670.44 9.9470.56 9.9870.71 10.0170.65
DDb 10 9.9370.64 9.9370.33 10.0270.51 9.9970.53
ƛ max (nm) 256 10 9.9670.60 9.9170.41 9.9770.80 9.9370.59
257 10 9.9570.91 9.9170.91 9.9870.42 9.9970.63
258 10 9.9570.90 9.9670.90 9.9770.86 9.9670.42
Tab – Tablet, Crm – Skin cream, Ont – Eye ointment, Inj – injection.
aSD – Single distilled,
bDD – Double distilled.
Table 6 Results of concentration determination of acyclovir in tablet, skin cream, eye ointment and injection.
Sample no Acyclovir found (g) Concentration (M 105)
Tablet Skin cream Eye ointment Injection Tablet Skin cream Eye ointment Injection
1 0.01007 0.00982 0.00973 0.00996 4.08 3.97 3.94 4.03
2 0.01010 0.00977 0.00998 0.00998 4.08 3.95 4.04 4.04
3 0.01012 0.00987 0.00977 0.00994 4.09 3.99 3.95 4.02
4 0.01000 0.01005 0.01010 0.00989 4.05 4.07 4.08 4.00
5 0.01003 0.00996 0.00973 0.00987 4.06 4.03 3.94 3.99
6 0.01005 0.01007 0.01014 0.01005 4.07 4.08 4.10 4.07
7 0.00994 0.01012 0.01000 0.00994 4.02 4.09 4.05 4.02
8 0.00998 0.01000 0.00996 0.00998 4.04 4.05 4.03 4.04
9 0.01007 0.00973 0.00998 0.01007 4.08 3.94 4.04 4.08
10 0.00996 0.01007 0.00973 0.00996 4.03 4.08 3.94 4.03
Mean 0.01003 0.00995 0.00991 0.00996 4.06 4.02 4.01 4.03
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metric ﬂask at the time of manufacturing at a temperature of
27 1C, while temperature in the laboratory varied within a range of
Δt¼74 1C. This difference was overcome by calculating uncer-
tainty value with estimation of temperature range and volume
dilatation coefﬁcient. Volume expansion of liquid was taken into
consideration, as it is quite higher than expansion of volumetric
ﬂask. The volume expansion coefﬁcient, γ, of water is 2.1 104/
1C. Thus uncertainty for 10 mL volumetric ﬂask ΔV10 was
calculated by Eq. (9).
ΔV10 ¼ V10  γ  Δt ð9Þ
where ΔV10, uncertainty of the 10 mL volumetric ﬂask; V10,
volume of the 10 mL volumetric ﬂask; γ, volume dilatation
coefﬁcient; Δt, temperature variation in the laboratory.
Thus, we obtain that uncertainty for volumetric ﬂask of 10 mL is
0.0084 mL, also assuming temperature variation is rectangular
distribution, standard uncertainty for 10 mL volumetric ﬂask due
to the temperature effect will be u(V10-temp) as shown in Eq. (10).
uðV10 tempÞ ¼
4 2:1 104  10ﬃﬃﬃ
3
p ¼ 0:0048 mL ð10Þ
Thus, standard uncertainty due to liberation of 10 mL volume of
10 mL volumetric ﬂask was calculated according to Eq. (11) andwas found to be 0.0058 mL. Standard relative uncertainty was
calculated and shown in Eq. (12).
uðV10Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðuðV10 cal
p
ÞÞ2 þ ðuðV10 repÞÞ2 þ ðuðV10 tempÞÞ2 ð11Þ
uðV10Þ ¼ 0:0058 mL
The standard relative uncertainty will be:
uðV10Þ
V10
¼ 5:76 104 ð12Þ
3.3.3. Uncertainty associated with the sample mass (msample)
Estimation of sample mass has three types of uncertainty sources
such as sensitivity, linearity, and repeatability. Mass of the sample
was expressed in kg for convenient traceability of results.
3.3.3.1. Sensitivity. The range of difference in weighed mass was
small and the same weighing balance was used each time. Thus,
uncertainty due to sensitivity of balance can be neglected.
3.3.3.2. Linearity. As the manufacturer data indicated a linearity
value of 0.0001 g, to determine overall uncertainty value, standard
uncertainty due to linearity was considered. A rectangular
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃs
Table 7 Summary of contribution to the measurement uncertainty.
Formulation Parameter Volume,
V10 (mL)
Sample concentration
C10 (M)
Mass sample,
msample (kg)
Recovery method Repeatability
Tablet Value 10 4.058 108 1.003 105 99.63 102 –
Standard uncertainty,
u(x)
5.76 103 1.15 109 2.91 107 1.98 102 3.30 103
RSU, u(x)/x 5.76 104 3.73 102 2.9 102 1.99 102 3.30 103
Eye ointment Value 10 4.01 108 9.91 106 99.75 102 –
Standard uncertainty,
u(x)
5.76 103 1.49 109 2.91 107 1.98 102 3.3 103
RSU, u(x)/x 5.76 104 3.71 102 2.94 102 1.99 102 3.3 103
Skin cream Value 10 4.02 108 9.95 106 10.10 101 –
Standard uncertainty,
u(x)
5.76 103 1.49 109 2.91 107 2.03 102 3.30 103
RSU, u(x)/x 5.76 104 3.71 102 2.93 102 2.01 102 3.30 103
Injection Value 10 4.03 108 9.96 106 99.50 102 –
Standard uncertainty,
u(x)
5.76 103 1.50 109 2.91 107 2.0 102 3.30 103
RSU, u(x)/x 5.76 104 3.73 102 2.93 102 2.01 102 3.30 103
Risk silhouette and uncertainty approximation 67distribution was assumed to convert contribution of linearity. It
was calculated and is expressed in Eq. (13).
u¼ 0:0001 10
3ﬃﬃﬃ
3
p ¼ 5:77 108 kg ð13Þ
3.3.3.3. Repeatability. Uncertainty associated with repeatability
was found to be 0:00028 103 kg.
3.3.4. Computation of relative uncertainty due to sample mass
Uncertainty due to sample mass u(msample) was calculated as
shown in Eq. (14).
uðmsampleÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2 ð5:77 108Þ2 þ ð0:00028 103Þ2
q
¼ 2:91
 107 kg
ð14Þ
From the values of Eq. (14) the relative uncertainty due to
sample mass in tablet, cream, eye ointment and injection was
calculated and found to be 2.90 102, 2.93 102, 2.94 102
and 2.93 102, respectively.
3.3.5. Uncertainty due to recovery of method
Results of recovery were evaluated as percentage recovery from
sample matrix of representative spiking. The value of recovery was
obtained from validation of method as discussed earlier. When a
‘spike’ is used to estimate recovery, the recovery of analyte from the
sample may differ from recovery of spike, so an uncertainty needs to
be evaluated. It was evaluated as Eq. (2) and U(Cspike) is calculated
by using Eq. (15) and results of uncertainty due to spiking
concentration of standard are represented in Table 7.uðACV sampleÞ
ACV sample
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
uðV10Þ
V10
 2
þ uðC10Þ
C10
 2
þ uðmsampleÞ
msample
 2
þ uðRm
Rm
sUðCspikeÞ ¼Cspike 
UðCbalÞ2
ðCbalÞ2
þ UðvÞ
2
ðvÞ2 ð15Þ
Therefore, the standard relative uncertainty of recovery of
method was calculated using uncertainty due to mass of
acyclovir (from balance), calibration of pipette, calibration of
ﬂask and temperature effect, which was found to be
1.97 107, 0.0058, 0.0029 and 0.0048, respectively. Com-
bined uncertainty due to these factors was found to be U(v)¼
0.00805 mL. Now using the Eq. (3) the standard relative
uncertainty due to recovery of method was calculated and
the results are represented in Table 7 for different formu-
lations.3.3.6. Uncertainty due to precision
Method validation results show the repeatability for determination
of acyclovir in terms of percentage RSD (0.335). This equation
can be used directly for calculation of CSU.
U(Rep)¼RSD
U(Rep)¼0.00335
3.3.7. Combined standard uncertainty (CSU)
The values of all the parameters having effect on acyclovir
determination are compiled up in Table 7 for tablet, skin cream,
eye ointment and injection, respectively.
These values were further used to calculate acyclovir quantity
by using Eq. (1) and thus, we obtained a quantity of 4.06 105,
4.00 105, 4.06 105 and 4.07 105 mol/kg for tablet, skin
cream, eye ointment and injection, respectively.
The CSU is calculated according to Eq. (16)ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Þ2 þ uðRepÞ
Rep
 2
ð16Þ
Fig. 5 Uncertainty proﬁle for acyclovir determination in (A) tablets, (B) skin cream, (C) eye ointment, (D) injection representing different
components contributing in overall uncertainty and showing the maximum effect due to concentration of sample.
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tablet ¼2.09 106 mol/kg
u (Acyclovirsample)
skin ¼2.10 106 mol/kg
u (Acyclovirsample)
ointment¼2.06 106 mol/kg
u (Acyclovirsample)
injection¼2.09 106 mol/kg
3.3.8. Expanded standard uncertainty (EU)
Expanded uncertainty of acyclovir in different sample matrices
was obtained by multiplying the combined standard uncertainty by
coverage factor, k¼2, at conﬁdence level of 95%, and the EU
(Acyclovirsample) is as shown
EU (Acyclovirsample)
tablet ¼4.17 106 mol/kg
EU (Acyclovirsample)
skin ¼4.20 106 mol/kg
EU (Acyclovirsample)
ointment¼4.12 106 mol/kg
EU (Acyclovirsample)
injection¼4.17 106 mol/kg
The contribution of different parameters in uncertainty is shown
individually for different sample matrices in Fig. 5.4. Conclusion
All analytical endeavors generate measurement data and hence,
should necessarily employ more or less appropriate statistical
techniques and methods of inference, to present and interpret the
data. The accurate estimation of variability is challenging. Baye-
sian approaches offer a different path to the assessment of
variability by combining probabilities estimated from detailed
study of sub-processes. Developing a new pharmaceutical product
requires the designing and testing of manufacturing and measure-
ment processes. The resulting process produces quality products
when measurements indicative of product quality are on targetwith minimum variance. In the present study, error propagation
break up statistical methods are successfully applied. This valida-
tion was based on the “total error” approach and it can be seen that
the method is suitable for routine analysis of acyclovir in different
formulations with minimum errors. In addition, it also illustrates
the application of cause–effect analysis in order to estimate the
uncertainty in the measuring of acyclovir from different pharma-
ceutical formulations through UV–vis spectrometry. The estima-
tion of uncertainty components proved to be a good way for the
experimental model to obtain contribution of the uncertainty in the
analytical result. In the present experiment, concentration of
sample is the major contributor towards uncertainty.References
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